Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02998567
Title Combination Study of Guadecitabine/ASTX727 and Pembrolizumab (HyPeR)
Acronym HyPeR
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Royal Marsden NHS Foundation Trust
Age Groups: adult | senior
Covered Countries GBR

Additional content available in CKB BOOST